RNA Biomarkers in Tissue Samples From Infants With Acute Myeloid Leukemia
NCT ID: NCT01229124
Last Updated: 2016-05-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
20 participants
OBSERVATIONAL
2010-10-31
2016-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
PURPOSE: This research study is studying RNA biomarkers in tissue samples from infants with acute myeloid leukemia.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Biomarkers in Bone Marrow Samples From Young Patients With Acute Myeloid Leukemia
NCT01298414
Biomarkers in Tissue Samples From Young Patients With Acute Myeloid Leukemia
NCT01229956
Studying Biomarkers in Cell Samples From Young Patients With Acute Myeloid Leukemia
NCT01057290
Biomarkers in Samples From Young Patients With Acute Myeloid Leukemia
NCT01247584
Biomarker Study in Tissue Samples From Patients With Acute Myeloid Leukemia
NCT01232842
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* Sequence the microRNAs present in 20 infant AML samples as a pilot study.
* Compare microRNAs present in infant AML samples to infant ALL samples that are being concurrently sequenced in a separate study to identify lineage- and translocation-specific microRNAs.
OUTLINE: This is a multicenter study.
Previously collected cryopreserved cells from diagnosis are sequenced using reverse transcriptase-PCR.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
RETROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
RNA analysis
nucleic acid sequencing
reverse transcriptase-polymerase chain reaction
laboratory biomarker analysis
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosis of acute myeloid leukemia
* Available cryopreserved cells from diagnosis
PATIENT CHARACTERISTICS:
* Not specified
PRIOR CONCURRENT THERAPY:
* Not specified
1 Year
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
Children's Oncology Group
NETWORK
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Michael Cleary, MD
Role: PRINCIPAL_INVESTIGATOR
Stanford University
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
COG-AAML11B1
Identifier Type: OTHER
Identifier Source: secondary_id
NCI-2011-02841
Identifier Type: REGISTRY
Identifier Source: secondary_id
AAML11B1
Identifier Type: OTHER
Identifier Source: secondary_id
AAML11B1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.